TSE:CTX Crescita Therapeutics (CTX) Stock Price, News & Analysis C$0.79 0.00 (0.00%) As of 06/4/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsBuy This Stock About Crescita Therapeutics Stock (TSE:CTX) Get Crescita Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.79▼C$0.7950-Day RangeC$0.75▼C$0.7952-Week RangeC$0.40▼C$0.79Volume1,164 shsAverage Volume42,290 shsMarket CapitalizationC$14.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue. Read More Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTX Stock News HeadlinesCrescita Therapeutics Inc. Announces Closing of ArrangementJune 3, 2026 | financialpost.comFCrescita Therapeutics Inc. Announces Closing of ArrangementJune 3, 2026 | financialpost.comFHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.July 22 at 1:00 AM | Stansberry Research (Ad)Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActivJune 1, 2026 | financialpost.comFCrescita Therapeutics Inc. Obtains Final Order Approving Plan of ArrangementMay 20, 2026 | financialpost.comFCrescita Obtains Shareholder Approval To Be Acquired By ClinActiv HoldingsMay 14, 2026 | financialpost.comFCrescita Reports First Quarter 2026 ResultsMay 11, 2026 | financialpost.comFCrescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv HoldingsApril 22, 2026 | financialpost.comFSee More Headlines CTX Stock Analysis - Frequently Asked Questions How have CTX shares performed this year? Crescita Therapeutics' stock was trading at C$0.48 at the start of the year. Since then, CTX stock has increased by 64.6% and is now trading at C$0.79. How were Crescita Therapeutics' earnings last quarter? Crescita Therapeutics Inc. (TSE:CTX) posted its earnings results on Monday, May, 11th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $5.64 million for the quarter. Crescita Therapeutics had a negative net margin of 1.38% and a negative trailing twelve-month return on equity of 2.07%. How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescita Therapeutics investors own include Baytex Energy (BTE), Argonaut Gold (AR), Birchcliff Energy (BIR), Crescent Point Energy (CPG), Enbridge (ENB) and IMV (IMV). Company Calendar Last Earnings5/11/2026Today7/22/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CTX CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.61 million Net Margins-1.38% Pretax MarginN/A Return on Equity-2.07% Return on Assets-8.26% Debt Debt-to-Equity Ratio17.34 Current Ratio2.80 Quick Ratio2.29 Sales & Book Value Annual SalesC$23.22 million Price / Sales0.63 Cash FlowC$0.66 per share Price / Cash Flow1.20 Book ValueC$0.77 per share Price / Book1.02Miscellaneous Outstanding Shares18,614,000Free FloatN/AMarket CapC$14.71 million OptionableNot Optionable Beta-1.55 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (TSE:CTX) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe smarter SpaceX play most investors will missOn July 1st, a brand-new blockchain went live. Traders flooded in. Memecoins launched by the hour. And accordi...Crypto 101 Media | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescita Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
